The anti-TNF-α agents adalimumab, infliximab and etanercept are indicated for a variety of autoimmune diseases such as rheumatoid arthritis (RA), Crohn's disease (CD), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and psoriasis (Pso). In some patients treated for nonpsoriatic conditions such as rheumatoid arthritis and Crohn's disease, these agents have been associated with the appearance of psoriasis (either its emergence or exacerbation)—a term previously coined TNF-α antagonist induced psoriasis.
Objective
This article reviews published data demonstrating this phenomenon.
Methods
Studies with English abstracts between 2000–2008, identified in MEDLINE and PUBMED with keywords anti-TNF, psoriasis, TNF-α antagonist and induced, were retrospectively reviewed.
Results
An association between use of anti-TNF agents and the appearance of psoriasis was seen in a total of 219 patients from 38 reports.
Conclusion
There is an association between use of anti-TNF agents and appearance of psoriasis, but the specific nature of the relationship is unknown. Recent studies help to delineate patient characteristics common among the group, as well as theorize proposed mechanisms for the emergence of psoriasis. At this time, however, further investigation into this multi-factorial condition is needed.
Get full access to this article
View all access options for this article.
References
1.
KruegerG., CallisK.Potential of Tumor Necrosis Factor Inhibitors in Psoriasis and Psoriatic Arthritis. Arch Dermatol.2004 Feb; (1402): 218–25.
2.
WeinbergJ.M.An Overview of Infliximab, Etanercept, Efalizumab and Alefacept as Biologic Therapy for Psoriasis. Clin Ther.2003; 25(10): 2488–505.
3.
BongartzT., SuttonA.J., SweetingM.J.Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA.2006 May 17; 295(19): 2275–85.
4.
MenterA., GottliebA., FeldmanS., Van VoorheesA.S., LeonardiC.L., GordonK.B., LebwohlM., KooJ.Y., ElmetsC.A., KormanN.J., BeutnerKr, BhushanR.Guidelines of Care for The Treatment of Psoriasis with Biologics. J Am Acad Dermatol.2008 May; 58(5): 826–50.
5.
WendlingD., BalblancJ.C., BriançonD.Onset or exacerbation of cutaneous psoriasis during TNF-alpha antagonist therapy. Joint, Bone, Spine.2008 Feb; 75(3): 315–8.
6.
de GannesG.C., GhoreishiM., PopeJ.Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol.2007 Feb; 143(2): 223–31.
7.
TortiD.C., FeldmanS.R.Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol.2007 Aug; 57(6): 1059–68.
8.
ThielenA.M., KuenzliS., SauratJ.H.Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology.2005 Jan; 211: 209–17.
KoJ.M., GottliebA.B., KerbleskiJ.F.Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatol Treat.2008 Oct. 1–8.
11.
CollamerA.N., GuerreroK.T., HenningJ.S.Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis and Rheum.2008; 59(7): 996–1001.
12.
BaetenD., KruithofE., Van den BoschF.Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?Ann Rheum Dis.2003 May; 62: 829–34.
13.
CohenJ.D., BourneriasI., BuffardV.Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol.2007; 34(2): 380–5.
14.
GottliebA.B., MathesonR.T., LoweN.A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol.2003 Dec; 139: 1627–32.
DereureO., GuillotB., JorgensenC., CohenJ.D., CombesB., GuilhouJ.J.Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol.2004; 151: 506–507.
17.
HaibelH., SpillerI., StrasserC.Unexpected new onset or exacerbating of psoriasis in treatment of active ankylosing spondylitis with TNF-alpha blocking agents [abstract]. Ann Rheum Dis.2004; 63(suppl): 405.
18.
KaryS., WormM., FritzJ.New onset of aggravating of psoriatic skin lesions in patients with definitive rheumatoid arthritis under-treatment with TNF-alpha antagonists: report of 8 cases [abstract]. Ann Rheum Dis.2004; 63(suppl): 276.
19.
PirardD., ArcoD., DebrouckereV., HeenenM.Anti-Tumor Necrosis Factor Alpha-Induced Psoriasiform Eruptions: Three Further Cases and Current Overview. Dermatology.2006; 213: 182–6.
VereaM., Del PozoJ., Yebra-PimentelM., PortaA., FonsecaE.Psoriasiform eruption induced by infliximab. Ann Pharmaco Ther.2004 Jan; 38: 54–7.
22.
FlendrieM., VissersW.H., CreemersM.C., de JongE.M., van de KerkhofP.C., van RielP.L.Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther.2005 Apr; 7: R666–76.
23.
MichaelssonG., KajermoU., MichaelssonA., HagforsenE.Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct?Br J Dermatol.2005; 153: 1243–4.
24.
PeramiquelL., PuigL., DalmauJ., RicartE., RoeE., AlomarA.Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol.2005 Apr; 30: 713–4.
25.
SfikakisP.P., IliopoulosA., ElezoglouA.Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum.2005 May; 52(8): 2513–8.
26.
Starmans-KoolM.J., PeetersH.R., HoubenH.H.Pustular skin lesions in patients treated with infliximab: report of two cases. Rheumatol Int.2005 Feb; 25: 550–2.
GoncalvesD.P., LaurindoI., ScheinbergM.A.The appearance of pustular psoriasis during antitumor necrosis factor therapy. J Clin Rheumatol.2006 Oct; 12: 262.
29.
KaryS., WormM., AudringH.New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis.2005 Sept; 65(3): 405–7.
30.
PeekR., Scott-JuppR., StrikeH., ClinchJ., RamananA.V.Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis.2006; 65: 1259.
31.
RitchlinC., TauskF.A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents. Ann Rheum Dis.2006 Aug; 65: 1541–4.
AngelucciE., CoccoA., ViscidoA., VerniaP., CaprilliR.Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm Bowel Dis.2007 Mar; 13: 1059–61.
34.
CavailhesA., Ingen-Housz-OroS., DjennaneS., RafaaM., Fiszeson- AlbalaF., WeberN.Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab. Ann Dermatol Venereol.2007; 134: 363–7. In French.
35.
GoirizR., DaudenE., Perez-GalaS., GuhlG., Garcia-DiezA.Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol.2007; 32: 176–9.
36.
LeeH.H., SongI.H., FriedrichM., GauliardA., DetertJ., RowertJ.Cutaneous side-effects in patients with rheumatic diseases during application of tumor necrosis factor-alpha antagonists. Br J Dermatol.2007; 156: 486–91.
37.
RichetteP., ViguierM., BachelezH., BardinT.Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?J Rheumatol.2007; 34: 438–9.
38.
RouxC.H., BrocqO., LecciaN., GiaccheroD., BreuilV., AlbertC.New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?J Rheumatol.2007; 34: 434–7.
39.
SeversG.A., LawlorT.H., PurcellS.M., AdlerD.J., ThompsonR.Cutaneous reaction to infliximab: report of psoriasis developing in 3 patients. Cutis.2007; 80: 231–7.
40.
TakahashiH., HashimotoY., Ishida-YamamotoA.Psoriasiform and pustular eruption induced by infliximab. The J Dermatol.2007; 34(7): 468–72.
41.
WegscheiderB.J., El-ShabrawiL., WegerM., ArdjomandN., HermannJ., AbererE.Adverse skin reactions to infliximab in the treatment of intraocular inflammation. Eye.2007; 21: 547–9.
42.
AslanidisS., PyrpasopoulouA., DoumaS.Tumor necrosis factor-α antagonist-induced psoriasis: yet another paradox in medicine. Clin Rheumatol.2008; 27(3): 377–80.
43.
Borrás-BlascoJ., Gracia-PerezA., Nuñez-CornejoC.Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther.2008; 33(3): 321–5.
44.
CarterJ.D., GerardH.C., and HudsonA.P.(2008). Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. Ann Rheum Dis.2008; 67(8): 1181–3.
45.
GrinblatB., and ScheinbergM.(2008). The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum.2008; 37(4): 251–5.
46.
HarrisonM.J., DixonW.G., WatsonK.D., KingY., GrovesR., HyrichK.L., and SymmonsD.P.M.Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNFα therapy. Results from the British Society for Rheumatology Biologics Register. ARD Online First. 2008.
47.
PapadavidE., GaziS., DalamagaM.Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol.2008; 22(3): 380–2.
48.
PaluckaA.K., BlanckJ.P., BennettL., PascualV., BanchereauJ.Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA.2005; 102: 3372–7.
49.
LaurindoI.M., ScheinbergM.Why do some biologic agents induce psoriasis or psoriasiform lesions?Nat Clin Pract Rheumatol.2008; 4(4): 168–9.
50.
SeckinD., DurusayC., SahinS.Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol.2004; 21: 577–579.
51.
LowesM.A., KikuchiT., Fuentes-DuculanJ.Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 Cells. J Invest Dermatol.2008; 128: 1207–1211.
52.
BlauveltA.T-Helper 17 Cells in Psoriatic Plaques and Additional Genetic Links between IL-23 and Psoriasis. J Invest Dermatol.2008; 128: 1064–1067.
53.
LeonardiC.L., KimballA.B., PappK.A., YeildingN., GuzzoC., WangY., LiS., DooleyL.T., GordeonK.B. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet.2008 May 17; 371(9625): 1665–74. Erratum in: Lancet. 2008 May 31;371(9627): 1838.
54.
PappK.A., LangleyR.G., LebwohlM., KruegerG.G., SzaparyP., YeildingN., GuzzoC., HsuM.C., WangY., LiS., DooleyL.T., ReichK., PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet.2008 May 17; 371(9625): 1675–84.
55.
CarterJ.D.Tumor Necrosis Factor Inhibition Causing Psoriasis? A More Plausible Explanation Exists. Ann Rheum Disease.2006; 65: 1680.
IshiharaT.Inhibition of Chlamydia trachomatis growth by IFN alpha: mechanisms and synergistic effect with interferon gamma and TNF alpha. Biomed Res.2005; 26: 179–185.
58.
InmanR.D.Early cytokine profiles in the joint define pathogen clearance and severity of arthritis in Chlamydia induced arthritis in rats. Arthritis Rheum.2006; 54: 499–507.
